Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease

BACKGROUND: Atherosclerotic cardiovascular disease is the leading cause of death and disability in the Western world. OBJECTIVE: To characterise adults with confirmed coronary heart disease (CHD) and primary heterozygous familial or non-familial hypercholesterolaemia or mixed dyslipidaemia who recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Steffens, Daniel, Bramlage, Peter, Müller, Julia, Dorn, Cornelia, Paar, W Dieter, Scheeff, Celine, Kasner, Mario, Rauch-Kröhnert, U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Coronary Artery Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130756/
https://www.ncbi.nlm.nih.gov/pubmed/34001653
http://dx.doi.org/10.1136/openhrt-2021-001572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130756/
https://www.ncbi.nlm.nih.gov/pubmed/34001653
http://dx.doi.org/10.1136/openhrt-2021-001572

Ejemplares similares